Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation

Valdeci Da Cunha, Doris M. Tham, Baby Martin-McNulty, Gary Deng, Jerrick J. Ho, Dennis W Wilson, John C Rutledge, Ronald Vergona, Mark E. Sullivan, Yi Xin Wang

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

Angiotensin converting enzyme (ACE) inhibitors prevent a wide variety of key events underlying atherogenesis. Whether these actions depend solely on reduction of angiotensin II (Ang II) generation is still to be determined. This study was undertaken to determine whether enalapril, an ACE inhibitor, prevents atherosclerosis and vascular inflammation induced by Ang II in apolipoprotein E-deficient (apoE-KO) mice. Subcutaneous infusion of Ang II (1.44 mg/(kg day)) for 4 weeks increased blood pressure and accelerated atherosclerosis development in the carotid arteries. The expression of the endothelial adhesion molecules E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), as well as the chemokines monocyte chemotactic protein-1 (MCP-1) and macrophage-colony stimulating factor (M-CSF) was up-regulated in the aortas of Ang II-treated mice. Enalapril co-treatment (25 mg/(kg day), in drinking water) prevented the development of atherosclerosis without affecting blood pressure or circulating cholesterol. In addition to preventing the Ang II-induced over-expression of adhesion molecules and chemokines in the aorta, enalapril up-regulated the expression of peroxisome proliferator-activated receptors (PPARs)-α and -γ, potential anti-inflammatory transcription factors. In the aortic arch, a lesion-prone site, the co-treatment with enalapril reduced the percentage of arterial wall occupied by macrophages and foam cells, medial sclerosis and elastin reduplication. Together, these data suggest an important role for Ang II-independent mechanisms in the antiatherogenic and anti-inflammatory effects of ACE inhibitors.

Original languageEnglish (US)
Pages (from-to)9-17
Number of pages9
JournalAtherosclerosis
Volume178
Issue number1
DOIs
StatePublished - Jan 2005

Fingerprint

Enalapril
Angiotensin II
Blood Vessels
Atherosclerosis
Inflammation
Angiotensin-Converting Enzyme Inhibitors
Apolipoproteins E
Chemokines
Aorta
Anti-Inflammatory Agents
Blood Pressure
Subcutaneous Infusions
Foam Cells
Peroxisome Proliferator-Activated Receptors
E-Selectin
Macrophage Colony-Stimulating Factor
Vascular Cell Adhesion Molecule-1
Elastin
Chemokine CCL2
Sclerosis

Keywords

  • ACE inhibitor
  • Angiotensin
  • Atherosclerosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. / Da Cunha, Valdeci; Tham, Doris M.; Martin-McNulty, Baby; Deng, Gary; Ho, Jerrick J.; Wilson, Dennis W; Rutledge, John C; Vergona, Ronald; Sullivan, Mark E.; Wang, Yi Xin.

In: Atherosclerosis, Vol. 178, No. 1, 01.2005, p. 9-17.

Research output: Contribution to journalArticle

Da Cunha, V, Tham, DM, Martin-McNulty, B, Deng, G, Ho, JJ, Wilson, DW, Rutledge, JC, Vergona, R, Sullivan, ME & Wang, YX 2005, 'Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation', Atherosclerosis, vol. 178, no. 1, pp. 9-17. https://doi.org/10.1016/j.atherosclerosis.2004.08.023
Da Cunha, Valdeci ; Tham, Doris M. ; Martin-McNulty, Baby ; Deng, Gary ; Ho, Jerrick J. ; Wilson, Dennis W ; Rutledge, John C ; Vergona, Ronald ; Sullivan, Mark E. ; Wang, Yi Xin. / Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. In: Atherosclerosis. 2005 ; Vol. 178, No. 1. pp. 9-17.
@article{664be5ba0a69455cb4049ca70cefef4c,
title = "Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation",
abstract = "Angiotensin converting enzyme (ACE) inhibitors prevent a wide variety of key events underlying atherogenesis. Whether these actions depend solely on reduction of angiotensin II (Ang II) generation is still to be determined. This study was undertaken to determine whether enalapril, an ACE inhibitor, prevents atherosclerosis and vascular inflammation induced by Ang II in apolipoprotein E-deficient (apoE-KO) mice. Subcutaneous infusion of Ang II (1.44 mg/(kg day)) for 4 weeks increased blood pressure and accelerated atherosclerosis development in the carotid arteries. The expression of the endothelial adhesion molecules E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), as well as the chemokines monocyte chemotactic protein-1 (MCP-1) and macrophage-colony stimulating factor (M-CSF) was up-regulated in the aortas of Ang II-treated mice. Enalapril co-treatment (25 mg/(kg day), in drinking water) prevented the development of atherosclerosis without affecting blood pressure or circulating cholesterol. In addition to preventing the Ang II-induced over-expression of adhesion molecules and chemokines in the aorta, enalapril up-regulated the expression of peroxisome proliferator-activated receptors (PPARs)-α and -γ, potential anti-inflammatory transcription factors. In the aortic arch, a lesion-prone site, the co-treatment with enalapril reduced the percentage of arterial wall occupied by macrophages and foam cells, medial sclerosis and elastin reduplication. Together, these data suggest an important role for Ang II-independent mechanisms in the antiatherogenic and anti-inflammatory effects of ACE inhibitors.",
keywords = "ACE inhibitor, Angiotensin, Atherosclerosis",
author = "{Da Cunha}, Valdeci and Tham, {Doris M.} and Baby Martin-McNulty and Gary Deng and Ho, {Jerrick J.} and Wilson, {Dennis W} and Rutledge, {John C} and Ronald Vergona and Sullivan, {Mark E.} and Wang, {Yi Xin}",
year = "2005",
month = "1",
doi = "10.1016/j.atherosclerosis.2004.08.023",
language = "English (US)",
volume = "178",
pages = "9--17",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation

AU - Da Cunha, Valdeci

AU - Tham, Doris M.

AU - Martin-McNulty, Baby

AU - Deng, Gary

AU - Ho, Jerrick J.

AU - Wilson, Dennis W

AU - Rutledge, John C

AU - Vergona, Ronald

AU - Sullivan, Mark E.

AU - Wang, Yi Xin

PY - 2005/1

Y1 - 2005/1

N2 - Angiotensin converting enzyme (ACE) inhibitors prevent a wide variety of key events underlying atherogenesis. Whether these actions depend solely on reduction of angiotensin II (Ang II) generation is still to be determined. This study was undertaken to determine whether enalapril, an ACE inhibitor, prevents atherosclerosis and vascular inflammation induced by Ang II in apolipoprotein E-deficient (apoE-KO) mice. Subcutaneous infusion of Ang II (1.44 mg/(kg day)) for 4 weeks increased blood pressure and accelerated atherosclerosis development in the carotid arteries. The expression of the endothelial adhesion molecules E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), as well as the chemokines monocyte chemotactic protein-1 (MCP-1) and macrophage-colony stimulating factor (M-CSF) was up-regulated in the aortas of Ang II-treated mice. Enalapril co-treatment (25 mg/(kg day), in drinking water) prevented the development of atherosclerosis without affecting blood pressure or circulating cholesterol. In addition to preventing the Ang II-induced over-expression of adhesion molecules and chemokines in the aorta, enalapril up-regulated the expression of peroxisome proliferator-activated receptors (PPARs)-α and -γ, potential anti-inflammatory transcription factors. In the aortic arch, a lesion-prone site, the co-treatment with enalapril reduced the percentage of arterial wall occupied by macrophages and foam cells, medial sclerosis and elastin reduplication. Together, these data suggest an important role for Ang II-independent mechanisms in the antiatherogenic and anti-inflammatory effects of ACE inhibitors.

AB - Angiotensin converting enzyme (ACE) inhibitors prevent a wide variety of key events underlying atherogenesis. Whether these actions depend solely on reduction of angiotensin II (Ang II) generation is still to be determined. This study was undertaken to determine whether enalapril, an ACE inhibitor, prevents atherosclerosis and vascular inflammation induced by Ang II in apolipoprotein E-deficient (apoE-KO) mice. Subcutaneous infusion of Ang II (1.44 mg/(kg day)) for 4 weeks increased blood pressure and accelerated atherosclerosis development in the carotid arteries. The expression of the endothelial adhesion molecules E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), as well as the chemokines monocyte chemotactic protein-1 (MCP-1) and macrophage-colony stimulating factor (M-CSF) was up-regulated in the aortas of Ang II-treated mice. Enalapril co-treatment (25 mg/(kg day), in drinking water) prevented the development of atherosclerosis without affecting blood pressure or circulating cholesterol. In addition to preventing the Ang II-induced over-expression of adhesion molecules and chemokines in the aorta, enalapril up-regulated the expression of peroxisome proliferator-activated receptors (PPARs)-α and -γ, potential anti-inflammatory transcription factors. In the aortic arch, a lesion-prone site, the co-treatment with enalapril reduced the percentage of arterial wall occupied by macrophages and foam cells, medial sclerosis and elastin reduplication. Together, these data suggest an important role for Ang II-independent mechanisms in the antiatherogenic and anti-inflammatory effects of ACE inhibitors.

KW - ACE inhibitor

KW - Angiotensin

KW - Atherosclerosis

UR - http://www.scopus.com/inward/record.url?scp=10044221986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10044221986&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2004.08.023

DO - 10.1016/j.atherosclerosis.2004.08.023

M3 - Article

C2 - 15585195

AN - SCOPUS:10044221986

VL - 178

SP - 9

EP - 17

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -